52P - Genetic variation of BCL3 is associated with five-year survival of NSCLC patients
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Lung and other Thoracic Tumours
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
F.D. Dimitrakopoulos1, A.G. Antonacopoulou1, A.E. Kottorou1, D. Dougenis2, C. Scopa3, H. Papadaki4, H. Kalofonos1
BCL3 is an atypical member of the IκB family and it has been found to be overexpressed in hematological malignancies and in some solid tumors, playing a pivotal role in tumor initiation and progression. A tag single nucleotide polymorphism of BCL3 (SNP; rs8100239, T>A) has been identified recently but there are no data relating to its role in non-small cell lung cancer (NSCLC) development.